He is currently Associate Professor at the University of Lund, Sweden, the Head of the Division of Clinical Tumour Immunology and Consultant in Oncology at University Hospital of Linkoping in Sweden.
He has published approximately 70 peer-reviewed articles and given approximately 40 congress presentations on these and other topics. He is a reviewer for several international scientific journals. He was the secretary and vice chairman of the Biological Development Group (BTDG) of the EORTC.
Prof Hakansson holds two international patents on predictive tests for immunotherapy of cancer.
Prof Hakansson’s research interest is in the development of biological therapeutics in cancer, especially in developing trial strategies / logistics for early clinical trials based on prediction of responders, monitoring therapeutic strategies in order to enable optimisation of the therapeutic efficacy.
Areas of particular research interest include:
- therapeutic antibodies
- angiogenesis inhibitors
- signal transduction inhibitors
Contact Prof. Leif Håkansson